In a new job - November 9, 2026
Malin Parkler takes on European role at Pfizer
Malin Parkler, who has led Pfizer’s Swedish organization for more than a decade, will take on a one-year assignment as Europe Cluster Lead, Global Hospital & Biosimilars, on December 1, 2026. Caglar Ceritoglu, North Europe Cluster President, will step in as Acting Country Lead in Sweden.
Pharma article - November 9, 2026
Opioid treatment linked to lower societal costs
Each person with opioid dependence who starts or stays in treatment for a year is associated with an estimated GBP 140,876 in lower societal costs in the UK. That is the finding of a new study by Lund-based Camurus and the Swedish Institute for Health Economics (IHE).
Agreement - November 9, 2026
AcuCort signs agreement for Zeqmelit with Kye Pharmaceuticals
The company has entered into an exclusive licence and distribution agreement with Canadian pharmaceutical company Kye Pharmaceuticals for Zeqmelit, a rapidly dissolving dexamethasone oral film, in Canada.
Pharma article - November 9, 2026
Cantargia announces second target for bispecific CAN14 antibody
Cantargia has announced IL-17 as the second target for the bispecific antibody CAN14.
Pharma Business - November 9, 2026
FDA starts inspection at Xspray’s drug manufacturer
Xspray Pharma says the US FDA has begun an inspection at NerPharMa, the contract manufacturer whose cGMP status must be cleared before the agency can approve the company’s cancer drugs Dasynoc and Nilopki. Xspray has also resolved on a rights issue of about SEK 90 million, which can be increased by about SEK 72 million through an over-allotment issue.
Clinical Trials - November 9, 2026
Novo’s ziltivekimab fails to cut heart events in full ZEUS data
Full results from Novo’s Phase 3 ZEUS trial confirm that the IL-6 inhibitor ziltivekimab did not reduce the risk of heart attack, stroke or cardiovascular death in people with atherosclerotic cardiovascular disease, chronic kidney disease and inflammation. The data were presented at the American Heart Association’s Scientific Sessions 2026 and published in the New England Journal of Medicine.
